Document Detail


Development and clinical experience with the new evidence-based tocolytic atosiban.
MedLine Citation:
PMID:  12190838     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The incidence of preterm birth has remained unchanged for the last few decades. This is due, in part, to the complex etiology of preterm labor, and the limited ability of tocolytic agents to prolong pregnancy as a result of limited efficacy and poor safety profiles. The recent introduction of the oxytocin antagonist, atosiban, represents a new generation of uterine-specific tocolytics, which are associated with more favorable safety profiles. This paper discusses the rationale behind the development of the oxytocin antagonists and provides a review of the phase II and III trials that have investigated atosiban. Also included is a retrospective analysis of 83 women assessed in the Vienna Medical School, providing an insight into the benefits associated with atosiban in the everyday clinical setting. The introduction of a safer tocolytic agent offers the potential to change the current approach to the management of preterm labor. This includes a prolonged period of treatment at earlier or later gestational ages and possibly an extended use to women with contraindications who would normally have been excluded from treatment, e.g. preterm premature rupture of the membranes.
Authors:
Peter Husslein
Related Documents :
16050538 - Experience of pain and analgesia with water and land births.
35978 - Pharmacologic inhibition of preterm labor.
7223808 - Short arrest of cervical dilatation: a risk for maternal/fetal/infant morbidity.
7633868 - The role of basic science in preventing low birth weight.
7377258 - Alternative birthing center: experience in a teaching obstetric service.
21667058 - Urinary ß(2)-microglobulin in very preterm neonates with chorioamnionitis.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Acta obstetricia et gynecologica Scandinavica     Volume:  81     ISSN:  0001-6349     ISO Abbreviation:  Acta Obstet Gynecol Scand     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-08-22     Completed Date:  2002-09-10     Revised Date:  2008-09-03    
Medline Journal Info:
Nlm Unique ID:  0370343     Medline TA:  Acta Obstet Gynecol Scand     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  633-41     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynecology, University of Vienna Medical School, Austria. peter.husslein@akh-wien.ac.at
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Female
Hormone Antagonists / pharmacology*,  therapeutic use
Humans
Infant, Newborn
Obstetric Labor, Premature / drug therapy,  prevention & control*
Pregnancy
Pregnancy Outcome
Tocolytic Agents / pharmacology*,  therapeutic use
Vasotocin / analogs & derivatives*,  pharmacology*,  therapeutic use
Chemical
Reg. No./Substance:
0/Hormone Antagonists; 0/Tocolytic Agents; 9034-50-8/Vasotocin; 90779-69-4/atosiban

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patterns of depressed mood across the menopausal transition: approaches to studying patterns in long...
Next Document:  Could an infectious trigger explain the differential maternal response to the shared placental patho...